Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia.

Abstract

Thirty-one pediatric patients with acute leukemia who had relapsed on either 6-mercaptopurine or 6-thioguanine were treated with beta-2'-deoxythioguanosine, which was administered as an iv infusion every 12 hours for three or six doses every 2 weeks. Severe nausea and vomiting and urate nephropathy were the dose-limiting toxic effects. Therapeutic responses occurred in four of 24 children with acute lymphocytic leukemia and in two of seven with acute nonlymphoblastic leukemia.

• Authors: G R Higgins, D C Jamin, N A Shore, R Momparler, G Hartman, S E Siegel
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 69 Issue 6 Pg. 699-701 (Jun 1985) ISSN: 0361-5960 [Print] United States
• PMID: 3860294 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Thionucleosides
• Uric Acid
• beta-2'-deoxythioguanosine
• Deoxyguanosine

Topics

• Acute Disease
• Acute Kidney Injury (chemically induced)
• Child
• Deoxyguanosine (analogs & derivatives, therapeutic use, toxicity)
• Drug Evaluation
• Humans
• Leukemia (drug therapy)
• Leukemia, Lymphoid (drug therapy)
• Nausea (chemically induced)
• Thionucleosides (therapeutic use, toxicity)
• Uric Acid (urine)
• Vomiting (chemically induced)